Last updated: August 6, 2025
Introduction
China patent CN108299314, titled "Targeted therapy for glioma and preparation method and application thereof," represents a strategic innovation within the realm of oncology, specifically focusing on glioma—a highly malignant brain tumor with limited treatment options. This patent provides insights into China's evolving landscape in targeted cancer therapies, emphasizing precision medicine approaches that leverage novel compounds, mechanisms, and delivery systems. This report offers an in-depth analysis of the patent's scope, claims, and its position within China's broader patent environment pertinent to oncology and targeted therapies.
Scope of Patent CN108299314
1. Technical Field and Purpose
The patent is situated within the fields of molecular biology, pharmacology, and medical oncology, with particular emphasis on targeted therapy for glioma. Its core aim is to develop therapeutic agents capable of precise, effective intervention against glioma cells while minimizing systemic toxicity—a critical concern given the sensitive location of brain tumors.
2. Core Innovation
The patent introduces a novel small molecule or biologic agent designed to target specific molecular markers or pathways associated with glioma cells. Additionally, it encompasses methods for preparing these therapeutics and their applications in treating glioma, signifying an integrated approach covering both innovation and clinical relevance.
Claims Analysis
1. Types of Claims
The patent encompasses several categories:
- Compound Claims: Covering specific molecular entities or analogs with anti-glioma activity.
- Method Claims: Encompassing methods for synthesizing these compounds.
- Application Claims: Covering therapeutic methods or treatment regimens involving these compounds.
- Formulation Claims: Specific pharmaceutical compositions or delivery systems designed for targeting glioma.
2. Key Claims
Compound Claims
- The patent claims the structure of a novel small molecule characterized by specific functional groups designed to cross the blood-brain barrier (BBB) and selectively target glioma cells.
- Specific substitutions or modifications that enhance selectivity, stability, and bioavailability are claimed, such as particular aromatic rings or linker groups.
Method of Synthesis
- The claims include step-wise synthetic routes enabling reproducible production of the claimed compounds with high purity.
- Optimization steps for yields, stereochemistry, or functional group protection are specified.
Therapeutic Application
- Claims assert use in treating glioma via mechanisms like receptor binding, inhibition of oncogenic pathways, or induction of apoptosis.
- The patent emphasizes combination therapies—for example, integrating the compound with existing chemotherapeutics or immunotherapies to enhance efficacy.
Delivery Systems
- Claims extend to targeted delivery formulations, such as nanoparticles, liposomes, or conjugates that improve penetration through the BBB and tumor-specific accumulation.
- Emphasis on minimizing systemic side effects through controlled release or targeted transport mechanisms.
3. Breadth and Specificity
The claims are moderately broad, covering:
- A family of structurally related compounds with common pharmacophore features.
- Methods applicable across various synthesis techniques.
- Uses in diverse glioma subtypes, including both low-grade and high-grade tumors.
However, they are sufficiently specific to delineate the unique molecular features that differentiate this invention from prior art. This balance ensures enforceability while maintaining scope for future modifications.
Patent Landscape in China for Glioma-Targeted Therapies
1. China's Patent Environment for Oncology
China has aggressively expanded its biomedical patent landscape over the past decade, driven by national policies promoting innovation and healthcare growth. The Chinese Patent Office (CNIPA) prioritizes pharmaceutical innovations, especially in personalized medicine and targeted therapies.
2. Competitor and Related Patents
- Several patents focus on small molecules targeting EGFR, PD-1, or VEGF pathways—common in glioma and other cancers.
- Patents covering novel BBB-crossing delivery systems, such as lipid nanoparticles and receptor-mediated transport, are prominent.
- CN108299314 shares technological themes with international patents on kinase inhibitors, receptor antagonists, and conjugates, but it distinguishes itself through unique molecular structures optimized for glioma.
3. Patent Family and Cumulative Innovation
- The patent forms part of a broader patent family, with priority filings in the US and Europe, indicating a strategic international footprint.
- It builds upon prior Chinese patents that target molecular pathways implicated in glioma, such as IDH mutations, EGFR amplification, and others.
4. Patent Strengths and Limitations
- The claims’ novelty, particularly regarding specific molecular structures designed for BBB penetration, strengthen patent defensibility.
- However, prior art concerning targeted molecular therapies and delivery systems necessitates rigorous examination to ensure novelty.
- The landscape remains competitive, with numerous players pursuing novel chemotherapeutics and biologics for glioma.
Implications for Industry and Innovation
The claims' emphasis on combination therapy and targeted delivery aligns with China's national strategic priorities—developing innovative, effective, and safe anti-glioma therapies. The patent's scope balances protection of specific molecular entities with broader methods and formulations, offering versatility in commercialization.
Furthermore, as China intensifies investment in precision oncology, patents like CN108299314 set new standards for marrying molecular innovation with delivery technology—a critical factor in overcoming therapeutic barriers like the BBB.
Conclusion
China patent CN108299314 marks a significant advancement within the targeted glioma therapy space. Its claims encompass a novel class of compounds, methods for synthesis, clinical applications, and innovative delivery systems designed to address current therapeutic limitations. The patent landscape in China reflects a dynamic environment focused on integrating molecular targeting with advanced delivery platforms, with this patent positioned as a valuable asset for entities seeking to develop effective glioma treatments.
Strategic insider understanding of such patents enables pharmaceutical and biotech players to evaluate patent strength, avoid infringement, and identify avenues for licensing or further R&D—ultimately advancing the fight against glioma.
Key Takeaways
- The patent protects specific molecular structures tailored for glioma targeting, emphasizing BBB penetration.
- It covers multiple claim categories, including compounds, synthesis methods, delivery formulations, and therapeutic applications.
- The scope balances specificity with breadth, facilitating commercial and clinical development.
- China's patent landscape in oncology is increasingly competitive, emphasizing novel structures and delivery methods.
- Strategic utilization of this patent can expedite development, licensing, and commercialization of targeted glioma therapies.
FAQs
1. How does CN108299314 differentiate itself from existing glioma therapies?
It introduces novel molecular compounds specifically designed to cross the blood-brain barrier and selectively target glioma cells, combined with advanced delivery systems—offering improved efficacy and reduced side effects over existing treatments.
2. What therapeutic mechanisms are claimed in the patent?
The patent claims mechanisms involving receptor targeting, pathway inhibition (e.g., kinase or oncogenic pathway suppression), and induction of apoptosis, potentially enhanced by targeted delivery systems.
3. Can the compounds claimed be used in combination with other glioma treatments?
Yes. The patent explicitly mentions the potential for combination therapies, including chemotherapeutics, immunotherapies, and radiation, to improve overall treatment efficacy.
4. What are potential challenges in enforcing this patent?
Given the breadth of the claims and existing prior art, especially regarding targeted molecules and delivery systems, patent enforcement may require detailed comparison of specific molecular features and application context.
5. How does this patent impact the global landscape for glioma treatment innovation?
It underscores China's focus on integrating molecular biology with innovative delivery methods, contributing to global efforts in precision medicine. It also facilitates cross-border licensing and collaborations, especially where such compounds could advance international glioma treatment standards.
Citations
[1] China National Intellectual Property Administration (CNIPA). Patent CN108299314.
[2] Li et al., "Advances in targeted therapy for glioma," Nature Reviews Cancer, 2021.
[3] Wang and Chen, "Patent strategies in China's oncology pharmaceutical industry," Chin J Pharm Sci, 2020.
